Results 221 to 230 of about 39,176 (275)
Some of the next articles are maybe not open access.
Journal of Clinical Psychopharmacology, 1997
Two hundred thirty-eight patients treated with either haloperidol or clozapine were investigated to shed more light on the incidence and severity of antipsychotic-induced liver enzyme increase. Serum glutamic-pyruvic transaminase (SGPT) increase was most frequently seen in both treatment groups.
M, Hummer +5 more
openaire +2 more sources
Two hundred thirty-eight patients treated with either haloperidol or clozapine were investigated to shed more light on the incidence and severity of antipsychotic-induced liver enzyme increase. Serum glutamic-pyruvic transaminase (SGPT) increase was most frequently seen in both treatment groups.
M, Hummer +5 more
openaire +2 more sources
American Journal of Psychiatry, 1990
Clozapine is a newly released antipsychotic that is associated with a higher prevalence of seizures than traditional neuroleptics. The authors describe four patients who developed seizure activity during clozapine treatment and provide recommendations for clinical management of this problem.
E, Haller, R L, Binder
openaire +2 more sources
Clozapine is a newly released antipsychotic that is associated with a higher prevalence of seizures than traditional neuroleptics. The authors describe four patients who developed seizure activity during clozapine treatment and provide recommendations for clinical management of this problem.
E, Haller, R L, Binder
openaire +2 more sources
Clinical Neuropharmacology, 2015
Clozapine is a major atypical antipsychotic drug used in treatment-resistant schizophrenia (Patel and Allin. Ther Adv Psychopharmacol 2011;1:25-29). It interferes with dopamine binding to D1, D2, D3, and D5 receptors but has high affinity to D4. It also has an anticholinergic effect and antagonizes α-adrenergic, histaminergic, and serotoninergic ...
Valentina, Bruno +2 more
openaire +2 more sources
Clozapine is a major atypical antipsychotic drug used in treatment-resistant schizophrenia (Patel and Allin. Ther Adv Psychopharmacol 2011;1:25-29). It interferes with dopamine binding to D1, D2, D3, and D5 receptors but has high affinity to D4. It also has an anticholinergic effect and antagonizes α-adrenergic, histaminergic, and serotoninergic ...
Valentina, Bruno +2 more
openaire +2 more sources
Clozapine—A dangerous drug in a clozapine-naïve subject
Forensic Science International, 2012Clozapine is a uniquely effective antipsychotic, but is very toxic in clozapine-naïve subjects. A 34-year-old male patient in a mental health facility, who was not prescribed clozapine, took 350 mg clozapine obtained from another patient at night. He was found dead the next morning. The presence of cardiomegaly related to obesity may have increased the
Stanworth, D. +2 more
openaire +3 more sources
Journal of Clinical Psychopharmacology, 1989
The discovery of clozapine represents such a combination of paradoxes, luck and unfortunate incidents that some people believe the history of clozapine should be entitled "The Clozapine Story" (Stille and Fischer-Cornelssen 1988). One paradox lies in the fact that clozapine is at the same time a very old drug and also one of the newest and most modern ...
openaire +2 more sources
The discovery of clozapine represents such a combination of paradoxes, luck and unfortunate incidents that some people believe the history of clozapine should be entitled "The Clozapine Story" (Stille and Fischer-Cornelssen 1988). One paradox lies in the fact that clozapine is at the same time a very old drug and also one of the newest and most modern ...
openaire +2 more sources
L'Encephale, 1993
Clozapine does not constitute a first-line treatment due to the occurrence of agranulocytosis. However, the benefit risk/ratio fully justifies its use in two situations: resistance to neuroleptics, intolerance to neuroleptics. There are no internationally recognized objective criteria to define resistance.
openaire +2 more sources
Clozapine does not constitute a first-line treatment due to the occurrence of agranulocytosis. However, the benefit risk/ratio fully justifies its use in two situations: resistance to neuroleptics, intolerance to neuroleptics. There are no internationally recognized objective criteria to define resistance.
openaire +2 more sources